Scalp psoriasis
Reading File
Finding Sources
Finding Sources
Searching PubMed
"scalp psoriasis" AND treatment
Reading File
Reading File
Reading Article
PMID: 37977294
Finding Sources
Finding Sources
Searching the Web
scalp psoriasis clinical features diagnosis treatment guidelines 2024 2025
Reading File
Finding Sources
Finding Sources
Reading File
?
It looks like my previous response got cut off before I delivered the final answer. Let me compile everything I gathered into a complete overview of scalp psoriasis now.
Scalp Psoriasis
Definition & Epidemiology
Scalp psoriasis is one of the most common sites of psoriatic involvement. It presents as a chronic, relapsing-remitting inflammatory condition mediated by T-cells and pro-inflammatory cytokines (IL-17, IL-23, TNF-α). It can occur in isolation or alongside plaque psoriasis elsewhere, and is strongly associated with psoriatic arthritis (PsA) - scalp involvement is an independent risk factor for PsA transition.
Clinical Features
| Feature | Description |
|---|---|
| Morphology | Discrete, well-demarcated erythematous plaques with thick silvery-white scale |
| Distribution | Scalp (often occipital), hairline, retroauricular areas, posterior neck |
| Scale type | Silvery-white; occasionally asbestos-like (pityriasis amiantacea) - scales adhering to hair shafts in clumps |
| Symptoms | Pruritus (often significant), burning, tenderness; cosmetic embarrassment from flaking |
| Hair loss | Alopecia occasionally develops - both scarring and non-scarring types reported; usually reversible |
Pityriasis amiantacea: thick, asbestos-like scales binding to hair tufts - psoriasis is the most common cause (also seen in seborrheic dermatitis, infected atopic dermatitis, tinea capitis).
Differential Diagnosis
The two most important conditions to distinguish are:
| Feature | Scalp Psoriasis | Seborrheic Dermatitis |
|---|---|---|
| Margins | Well-defined, discrete plaques | Ill-defined, diffuse |
| Scale | Thick, silvery-white | Greasy, yellowish |
| Pruritus | Moderate-severe | Mild-moderate |
| Hair | Dry and brittle | Oily/greasy |
| Body sites | Elbows, knees, nails | Nasolabial folds, chest, eyebrows |
"Sebopsoriasis": overlap of both conditions exists in some patients and can be difficult to distinguish.
Other differentials to consider:
- Tinea capitis (especially in prepubertal children; send for KOH/culture)
- Dermatomyositis (posterior scalp erythema, associated signs)
- Atopic dermatitis
- Lichen planopilaris
- Discoid lupus erythematosus
Pathophysiology
Scalp psoriasis shares the same immunopathology as plaque psoriasis:
- Th17/IL-17A axis is the dominant driver
- Keratinocyte hyperproliferation (turnover days vs. weeks in normal skin)
- Neutrophil recruitment → Munro microabscesses (histological hallmark)
- Parakeratosis, acanthosis, elongated rete ridges on biopsy
Assessment of Severity
- PSSI (Psoriasis Scalp Severity Index) - specific for scalp
- sDLQI or standard DLQI for quality of life impact
- Mild: limited patches, minimal symptoms
- Moderate-Severe: extensive involvement, significant itch, social/psychological impact
Treatment
Treatment is staged by severity. The hair creates a physical barrier to topical delivery, so vehicle formulation (shampoo, foam, gel, lotion) is as important as the active agent.
Step 1 - Descaling (All Grades)
Always start by removing scale to allow penetration of active agents:
- Salicylic acid 5-10% (keratolytic) - shampoo or gel
- Coal tar shampoos
- Coconut oil / olive oil overnight occlusion
Step 2 - Mild to Moderate Disease: Topical Therapy
First-line: Combination Calcipotriol/Betamethasone dipropionate
The most evidence-based first-line option:
- Calcipotriol + betamethasone dipropionate (gel or foam formulation for scalp) achieves clearing or minimal disease in ~70% of patients with scalp psoriasis
- Applied once daily for 4 weeks (induction), then as needed
Topical Corticosteroids (monotherapy)
- High-potency (Class I-II): clobetasol propionate 0.05% foam/shampoo, betamethasone valerate
- Available as shampoos, foams, solutions for scalp use
- Short-term use; risk of atrophy, HPA-axis suppression with prolonged use
- Leave-on vs. rinse-off formulations (shampoos have lower systemic absorption)
Vitamin D3 Analogues (monotherapy)
- Calcipotriol (calcipotriene) - ~60% PASI reduction at 8 weeks as monotherapy
- Can cause local irritation on the face/scalp margins
Other Topical Options
- Tar preparations: anti-inflammatory, antipruritic; cosmetically less acceptable
- Tazarotene (topical retinoid): second-line; can cause irritation
- Anthralin (dithranol): more used in day-care/inpatient settings in Europe
Step 3 - Moderate to Severe / Refractory: Systemic & Biologic Therapy
When topical therapy fails or disease is extensive:
Conventional Systemics
| Drug | Notes |
|---|---|
| Methotrexate | Weekly oral/SC; monitor LFTs, CBC |
| Ciclosporin | Fast-acting; nephrotoxic with long-term use |
| Acitretin | Retinoid; teratogenic; useful in pustular variants |
Phototherapy
- Narrowband UVB (NB-UVB) for scalp - requires specialized scalp comb attachments
- Useful when topical therapy is insufficient
Biologics (preferred for moderate-severe)
Based on a 2024 network meta-analysis (JAAD, PMID 37977294) of systemic therapies for scalp psoriasis, IL-17 inhibitors and IL-23 inhibitors show superior scalp clearance over TNF-α inhibitors and conventional agents:
| Class | Agents | Key Point |
|---|---|---|
| IL-17A inhibitors | Secukinumab, ixekizumab, bimekizumab | High scalp clearance rates; fast onset |
| IL-23 inhibitors | Guselkumab, risankizumab, tildrakizumab | Durable response |
| IL-12/23 inhibitor | Ustekinumab | Effective; less potent than IL-17i |
| TNF-α inhibitors | Adalimumab, etanercept, infliximab | Effective but lower scalp-specific response vs. newer agents |
| TYK2 inhibitor | Deucravacitinib (oral) | Newer oral option; 2024 meta-analysis (PMID 38306122) confirms efficacy |
A 2024 TYK2/PDE4 inhibitor meta-analysis (PMID 37997745) specifically for scalp psoriasis confirmed efficacy of deucravacitinib and apremilast in scalp-specific outcomes.
Special Considerations
- Psoriatic arthritis risk: Scalp, nail, and inverse psoriasis are the three skin sites most strongly associated with PsA development - screen patients regularly with PEST or PASE questionnaires
- Alopecia: Usually non-scarring and reversible with treatment; rarely scarring. Seen more with TNF inhibitor-induced psoriasis
- Ear canal involvement: In ~18% of patients with systemic psoriasis; retroauricular fold is a classic site
- Pregnancy: Avoid systemic retinoids (teratogenic), methotrexate (abortifacient); biologics (IL-17i, TNF-α inhibitors) may be considered with specialist guidance
- Children: Consider tinea capitis before diagnosing scalp psoriasis; pityriasis amiantacea in prepubertal children - up to 1/3 eventually develop psoriasis
Prognosis
Scalp psoriasis is chronic and relapsing. Most patients achieve good control with appropriate topical therapy. Biologic therapy has transformed outcomes for severe or refractory cases. Quality of life impact is significant and should guide treatment intensity.
Sources: Dermatology 2-Volume Set 5e (Bolognia); Fitzpatrick's Dermatology; Rheumatology 2-Volume Set (Elsevier 2022); PMID 37977294; PMID 37997745; PMID 38306122
This is a shared conversation. Sign in to Orris to start your own chat.